Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

December 13, 2022

https://www.globenewswire.com/news-release/2022/12/13/2572587/14025/en/Arbutus-Completes-Enrollment-in-its-Phase-2a-Clinical-Trial-Combining-AB-729-with-NA-Therapy-and-Peginterferon-alfa-2a-in-Patients-with-Chronic-Hepatitis-B-Virus-Infection.html

Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg

Initial data from IFN phase expected in the first half of 2023

Read more at globenewswire.com

Related news for (ABUS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.